Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Dosing Is Achilles Heel For Pfizer’s First Candidate
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
You may also be interested in...
Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III
A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.
Novo Nordisk’s Obesity Drug Activities Break UK Rules Again
The company has been found in breach of the UK code once again for its work with pharmacists, although this time Novo Nordisk has escaped the heaviest censure.
Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets
Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.